Your browser doesn't support javascript.
loading
Measuring aggregates, self-association, and weak interactions in concentrated therapeutic antibody solutions.
Chaturvedi, Sumit K; Parupudi, Arun; Juul-Madsen, Kristian; Nguyen, Ai; Vorup-Jensen, Thomas; Dragulin-Otto, Sonia; Zhao, Huaying; Esfandiary, Reza; Schuck, Peter.
Afiliação
  • Chaturvedi SK; Dynamics of Macromolecular Assembly Section, Laboratory of Cellular Imaging and Macromolecular Biophysics, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health , Bethesda, MD, USA.
  • Parupudi A; Department of Dosage Form Design and Development, Biopharmaceuticals R&D, AstraZeneca , Gaithersburg, MD, USA.
  • Juul-Madsen K; Dynamics of Macromolecular Assembly Section, Laboratory of Cellular Imaging and Macromolecular Biophysics, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health , Bethesda, MD, USA.
  • Nguyen A; Biophysical Immunology Laboratory, Department of Biomedicine, Aarhus University , Aarhus, Denmark.
  • Vorup-Jensen T; Dynamics of Macromolecular Assembly Section, Laboratory of Cellular Imaging and Macromolecular Biophysics, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health , Bethesda, MD, USA.
  • Dragulin-Otto S; Biophysical Immunology Laboratory, Department of Biomedicine, Aarhus University , Aarhus, Denmark.
  • Zhao H; Department of Dosage Form Design and Development, Biopharmaceuticals R&D, AstraZeneca , Gaithersburg, MD, USA.
  • Esfandiary R; Dynamics of Macromolecular Assembly Section, Laboratory of Cellular Imaging and Macromolecular Biophysics, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health , Bethesda, MD, USA.
  • Schuck P; Department of Dosage Form Design and Development, Biopharmaceuticals R&D, AstraZeneca , Gaithersburg, MD, USA.
MAbs ; 12(1): 1810488, 2020.
Article em En | MEDLINE | ID: mdl-32887536
ABSTRACT
Monoclonal antibodies are a class of biotherapeutics used for an increasing variety of disorders, including cancer, autoimmune, neurodegenerative, and viral diseases. Besides their antigen specificity, therapeutic use also mandates control of their solution interactions and colloidal properties in order to achieve a stable, efficacious, non-immunogenic, and low viscosity antibody solution at concentrations in the range of 50-150 mg/mL. This requires characterization of their reversible self-association, aggregation, and weak attractive and repulsive interactions governing macromolecular distance distributions in solution. Simultaneous measurement of these properties, however, has been hampered by solution nonideality. Based on a recently introduced sedimentation velocity method for measuring macromolecular size distributions in a mean-field approximation for hydrodynamic interactions, we demonstrate simultaneous measurement of polydispersity and weak and strong solution interactions in a panel of antibodies with concentrations up to 45 mg/mL. By allowing approximately an order of magnitude higher concentrations than previously possible in sedimentation velocity size distribution analysis, this approach can substantially improve efficiency and sensitivity for characterizing polydispersity and interactions of therapeutic antibodies at or close to formulation conditions.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Agregados Proteicos / Anticorpos Monoclonais Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Agregados Proteicos / Anticorpos Monoclonais Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article